E-LIB Suche - Ergebnisse für: Webersinke, G

1

89P ctDNA as an unifiable biomarker to predict response to ..:

Kirchweger, P. ; Doleschal, B. ; Kupferthaler, A....
ESMO Open. 9 (2024) - p. 102315 , 2024

Link: https://doi.org/10.1016/..

2

301P Homologous recombination repair (HRR) deficiency in bi..:

Mavroeidi, I. ; Seyed Mohammad, T.W. ; Webersinke, G....
Annals of Oncology. 35 (2024) - p. S127 , 2024

Link: https://doi.org/10.1016/..

3

Understanding homologous recombination repair deficiency in..:

Mavroeidi, I.-A. ; Burghofer, J. ; Kalbourtzis, S....
ESMO Open. 9 (2024) 8 - p. 103630 , 2024

Link: https://doi.org/10.1016/..

4

88P Circulating tumor DNA (ctDNA) as precision medicine mar..:

Kirchweger, P. ; Doleschal, B. ; Kupferthaler, A....
ESMO Open. 9 (2024) - p. 102314 , 2024

Link: https://doi.org/10.1016/..

5

76P Prediction of response to palliative chemotherapy by ci..:

Kirchweger, P. ; Kupferthaler, A. ; Burghofer, J....
ESMO Open. 8 (2023) 1 - p. 100934 , 2023

Link: https://doi.org/10.1016/..

6

Bevacizumab mitigates codon-specific effects of trifluridin..:

Doleschal, B. ; Taghizadeh, H. ; Lentner, T....
ESMO Open. 8 (2023) 6 - p. 102064 , 2023

Link: https://doi.org/10.1016/..

7

Erfassung von erblichem Dickdarm- und Gebärmutterkrebs: Kon..:

Wimmer, K. ; Hulla, W. ; Zschocke, J....
Der Onkologe. 26 (2020) 9 - p. 846-855 , 2020

Link: https://doi.org/10.1007/..

8

P02.10Aggressiveness of meningiomas is predicted by cell im..:

Spiegl-Kreinecker, S ; Lötsch, D ; Neumayer, K...
Neuro-Oncology. 20 (2018) suppl_3 - p. iii274-iii274 , 2018

Link: https://doi.org/10.1093/..

9

Switch of the mutation type of the NPM1 gene in acute myelo..:

Webersinke, G ; Kranewitter, W ; Deutschbauer, S...
Blood Cancer Journal. 4 (2014) 6 - p. e221-e221 , 2014

Link: https://doi.org/10.1038/..

10

P04.24 * MUTATIONS OF THE TERT PROMOTER CORRELATE WITH ENHA..:

Spiegl-Kreinecker, S. ; Loetsch, D. ; Laaber, M....
Neuro-Oncology. 16 (2014) suppl 2 - p. ii42-ii42 , 2014

Link: https://doi.org/10.1093/..

11

Pathogenetic and clinical impact of JAK2 mutations in chron..:

Webersinke, G. ; Rumpold, Holger
memo - Magazine of European Medical Oncology. 2 (2009) 2 - p. 89-93 , 2009

Link: https://doi.org/10.1007/..

12

15 Molecular aspects of barrier mechanisms in the developin..:

Bauer, H.C. ; Webersinke, G. ; Bauer, H.
International Journal of Developmental Neuroscience. 14 (1996) S1 - p. 54-54 , 1996

Link: https://doi.org/10.1016/..

13

Comparison of gene expression of extracellular matrix molec..:

Webersinke, G. ; Bauer, H. ; Amberger, A...
Biochemical and Biophysical Research Communications. 189 (1992) 2 - p. 877-884 , 1992

Link: https://doi.org/10.1016/..

14

Bevacizumab mitigates codon-specific effects of trifluridin..:

Doleschal, B ; Taghizadeh, H ; Lentner, T...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774958/. , 2023

Link: http://www.ncbi.nlm.nih...

15

P04.24MUTATIONS OF THE TERT PROMOTER CORRELATE WITH ENHANCE..:

Spiegl-Kreinecker, S ; Loetsch, D ; Laaber, M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185501/. , 2014

Link: http://www.ncbi.nlm.nih...